58results about How to "Induce expression" patented technology

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

The present invention relates generally the field of genetics, in particular methods, compositions and systems for controlling the inducible expression of transgenes, while eliminating background expression of transgene expression. The present invention relates to methods of use of the compositions and systems as disclosed herein for controlling the inducible expression of transgenes while eliminating background expression of transgene expression, such as use in, for example, the in generation of transgenic animals, use in therapeutic application and use in assays. In some embodiments, the present invention relates to a system of controlled expression of RNAi molecules which target binding sites in the untranslated regions of transgene, thereby the expression of the transgene is modulated and leakiness is reduced. The compositions and methods of the present invention can be used to for therapy, prophylaxis, research and diagnostics in diseases and disorders which afflict mammalian species, generation of transgenic animals, in the study of biological processes as well as for enhance performance of agricultural crops.

A method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), includes administering a histone deacetylase (HDAC) inhibitor in a subject in need thereof. The HDAC inhibitor includes sodium butyrate or sodium phenylbutyrate.

A light-emitting diode includes a substrate, a compound semiconductor layer including a p-n junction-type light-emitting part formed on the substrate, an electric conductor disposed on the compound semiconductor layer and formed of an electrically conductive material optically transparent to the light emitted from the light-emitting part and a high resistance layer possessing higher resistance than the electric conductor and provided in the middle between the compound semiconductor layer and the electric conductor. In the configuration of a light-emitting diode lamp, the electric conductor and the electrode disposed on the semiconductor layer on the side opposite to the electric conductor across the light-emitting layer are made to assume an equal electric potential by means of wire bonding. The light-emitting diode abounds in luminance and excels in electrostatic breakdown voltage.

The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.

A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.

A light-emitting diode includes a substrate, a compound semiconductor layer including a p-n junction-type light-emitting part formed on the substrate, an electric conductor disposed on the compound semiconductor layer and formed of an electrically conductive material optically transparent to the light emitted from the light-emitting part and a high resistance layer possessing higher resistance than the electric conductor and provided in the middle between the compound semiconductor layer and the electric conductor. In the configuration of a light-emitting diode lamp, the electric conductor and the electrode disposed on the semiconductor layer on the side opposite to the electric conductor across the light-emitting layer are made to assume an equal electric potential by means of wire bonding. The light-emitting diode abounds in luminance and excels in electrostatic breakdown voltage.

The invention relates to methods for treating a subject by manipulating HER-2 on a cell as well as related products. The methods include methods of treating cancer using fatty acid oxidation inhibitors and HER-2 binding molecules such as antibodies and fragments thereof.

The invention relates to methods, compositions, and kits for combination therapy of diabetes and diabetes-related diseases and conditions (e.g., obesity). The invention finds use in patients suffering from or at risk for diabetes or diabetes-related conditions generally, and in patients also suffering from or at risk for fluid retention (e.g., edema, congestive heart failure) and / or in need of synergistic anti-inflammatory, anti-hypertensive, and anti-diabetic effect.

Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.

The invention relates to Tenascin-C and peptides that bind thereto. According to the invention, Tenascin-C or peptides and antibodies that bind thereto can be used to treat or prevent vascular diseases, either alone or in combination with therapeutic agents or cells that have cardioplastic potential.

There is disclosed a fibrocyte-based vaccine formulations made from isolated fibrocytes. There is further disclosed a method for establishing an immune response against a specific antigen by administering a fibrocyte-based vaccine formulation, such as one made by pulsing fibrocytes in culture with the antigen peptide or protein, or by fusing tumor cells (whole cells or membrane fragments thereof) with fibrocytes.

Disclosed are means, methods and compositions of matter useful for treatment of spinal muscular atrophy. In one embodiment, stem cells of the mesenchymal type are modified to enhance anti-inflammatory and regenerative potential in a manner to prevent disease, inhibit progression and / or reverse existing disease. In other embodiments combinations of mesenchymal stem cells together with extracts and / or products derived from said mesenchymal stem cells are administered for prevention, inhibition of progression and / or reversion of spinal muscular atrophy.

Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.

Method for the identification and isolation of expressed nucleic acid sequences that are associated with disease resistance of a plant against a plant pathogen, isolated nucleic acid molecules and variants and / or homologues thereof, constructs, plants and polypeptides encoded by said nucleotide sequences and the use of these sequences in the development of resistance in plants against pathogens.

The present invention relates generally the field of genetics, in particular methods, compositions and systems for controlling the inducible expression of transgenes, while eliminating background expression of transgene expression. The present invention relates to methods of use of the compositions and systems as disclosed herein for controlling the inducible expression of transgenes while eliminating background expression of transgene expression, such as use in, for example, the in generation of transgenic animals, use in therapeutic application and use in assays. In some embodiments, the present invention relates to a system of controlled expression of RNAi molecules which target binding sites in the untranslated regions of transgene, thereby the expression of the transgene is modulated and leakiness is reduced. The compositions and methods of the present invention can be used to for therapy, prophylaxis, research and diagnostics in diseases and disorders which afflict mammalian species, generation of transgenic animals, in the study of biological processes as well as for enhance performance of agricultural crops.

This invention relates in general to a mesenchymal stem cell (MSC) therapy. This invention further relates to the isolation and applications of gingiva derived mesenchymal stem cells. More particularly, this invention relates to the isolation and applications of the neural crest derived gingiva mesenchymal stem cells and / or mesoderm derived gingiva mesenchymal stem cells. This invention also relates to a composition comprising a neural crest derived gingiva mesenchymal stem cell and / or a mesoderm derived gingiva mesenchymal stem cell. This composition may be used for wound healing and / or in the treatment of inflammatory and / or autoimmune diseases.

The present invention relates to a process for varying a trait of monocot plants, wherein the process comprises the step of transforming a monocot plant with a recombinant plasmid containing an OsCc1 promoter and a desired nucleic acid.

The present invention relates to methods of inducing expression of an epigenetically silenced gene, RASSF1A, in cells, particularly human cells, such as cancer cells. It also relates to methods of treating an individual, prophylactically or therapeutically, for cancer in which RASSF1A is epigenetically silenced.

The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using IL-22 cytokine signaling and / or downstream targets of IL-22 cytokine signaling (e.g., STAT3, DOT1L, SUZ12, EED) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through IL-22 cytokine signaling.

The invention relates to a method of influencing angiogenesis by administering a of a compound in a pharmaceutically compatible carrier selected from the group consisting of (i) CD66a, a CD66a variant, CD66a fragments or CD66a-derived glycostructures, or CD66a ligands, or (ii) of anti-CD66a specific antibodies and anti-sense oligonucleotides.

Methods and compositions are provided for determining whether target, e.g., an endogenous or novel (non-endogenous), nucleic acid sequence of a neuronal cell is involved in sensory function. In practicing the subject methods, a neuronal cell selective vector including a modulating domain for a neuronal cell nucleic acid sequence, optionally having a domain encoding a directly detectable product, is administered to an animal. Sensory function in harvested neuronal cells is then evaluated to determine whether the target nucleic acid sequence is involved in sensory function. Also provided are compositions, kits, and systems for practicing the subject methods.

A transplantable composition comprises retinal pigment epithelium cells modified to induce expression and / or secretion of a therapeutic molecule, that can be used to prevent and / or treat disease.

A rapid and sensitive radiometric assay for assessing the activity of cytochrome P450 (CYP) 3A4 / 5 and the potential of an analyte to inhibit CYP3A4 / 5 activity or induce CYP3A4 / 5 expression is described. All the steps of the assay, including incubations, product separation, and radioactivity counting are preferably performed in a multiwell format, which can be automated.

The invention provides methods for detecting and analyzing protein-protein interactions and agonists and antagonists thereof, detecting and analyzing protein sequences, and regulatable gene expression in multicellular organisms or cells therefrom.

A method for regulating expression of a virulence gene of Agrobacterium is described. The method comprises the steps of stimulating cereal cells, such as sorghum, so as to produce an active, typically phenolic, compound and exposing the Agrobacterium to this compound. The compound induces expression of the virulence gene of the Agrobacterium, effecting T-DNA transfer from the Agrobacterium to the cereal cells, which are thereby transformed.

The invention relates to methods and media for inducing or maintaining a mature hepatocyte phenotype in a cell, the method comprising the step of cultivation cells in a cell culture medium comprising at least 10 mg amino acids / ml medium, wherein at least 50% (w / w) of the concentration of said amino acids in said medium is provided by one up to five amino acids and, with the proviso that said one up to five amino acids is not one of Thr, Tyr, Cys, Met, Arg and His.

A method for regulating expression of a virulence gene of Agrobacterium is described. The method comprises the steps of stimulating cereal cells, such as sorghum, so as to produce an active, typically phenolic, compound and exposing the Agrobacterium to this compound. The compound induces expression of the virulence gene of the Agrobacterium, effecting T-DNA transfer from the Agrobacterium to the cereal cells, which are thereby transformed.